Please login to the form below

Not currently logged in
Email:
Password:

postmenopausal osteoporosis

This page shows the latest postmenopausal osteoporosis news and features for those working in and with pharma, biotech and healthcare.

CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

postmenopausal women with osteoporosis. ... After a fracture, postmenopausal women with osteoporosis are five times more likely to fracture in the subsequent year, and these fractures can be life-changing.

Latest news

  • Amgen and UCB’s Evenity finally approved, but with label warnings Amgen and UCB’s Evenity finally approved, but with label warnings

    The CDER's Hylton Joffe. “Today’s approval provides women with postmenopausal osteoporosis who are at high risk of fracture with a new treatment that will reduce this risk,” said Hylton ... Amgen’s R&D head David Reese welcomed the FDA approval,

  • UCB looks to pipeline with five years left for twin blockbusters UCB looks to pipeline with five years left for twin blockbusters

    25%. The first new product to hit the market is osteoporosis candidate Evenity (romosozumab), co-developed and co-marketed with Amgen.  The drug has suffered setbacks in reaching the market, being ... to treat osteoporosis in postmenopausal women at

  • Evenity back on track with FDA panel blessing in osteoporosis Evenity back on track with FDA panel blessing in osteoporosis

    The panel backed the use of the drug in postmenopausal women with osteoporosis at high risk for fracture by 18-1. ... risk. Amgen’s R&D head Davide Reese said that having additional treatment options for postmenopausal women with osteoporosis is

  • Amgen's Kyprolis scarred by head-to-head duel with Velcade Amgen's Kyprolis scarred by head-to-head duel with Velcade

    Romosozumab filed  . There was some better news for Amgen and partner UCB this week when the FDA started its review of romosozumab, their drug candidate for the treatment of osteoporosis in ... postmenopausal women at increased risk of fracture.

  • Merck decision to drop odanacatib lifts UCB/Amgen Merck decision to drop odanacatib lifts UCB/Amgen

    The company prematurely halted a phase III trial of the drug in 2012 after seeing a clear benefit on fractures rates in postmenopausal women with osteoporosis, although it did note at ... fractures in postmenopausal women with osteoporosis compared to

More from news
Approximately 1 fully matching, plus 31 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics